key: cord-0884512-u4slinzr authors: De-Los-Rios-Pinto, Abraham; Fernandez-Guzman, Daniel; Soriano-Moreno, David R.; Sangster-Carrasco, Lucero; Morocho-Alburqueque, Noelia; Pinedo-Soria, Antony; Murrieta-Ruiz, Valentina; Diaz-Corrales, Angelica; Alave, Jorge; Nieto-Gutierrez, Wendy; Armando Gonzales-Zamora, Jose title: Factors associated with the intention to participate in COVID-19 vaccine clinical trials: A cross-sectional study in Peru date: 2022-04-07 journal: Vaccine DOI: 10.1016/j.vaccine.2022.04.003 sha: 688a4f9fe60675bcec1bb2f254faf884d70100d0 doc_id: 884512 cord_uid: u4slinzr OBJECTIVE: To evaluate the factors associated with the intention to participate in COVID-19 vaccine clinical trials in the Peruvian population. METHODS: Cross-sectional study and secondary analysis of a database that involved Peruvian population during September 2020. The Poisson regression model was used to estimate the associated factors. RESULTS: Data from 3231 individuals were analyzed, 44.1% of whom intended to participate in COVID-19 vaccine clinical trials. Factors associated with the outcome were being male (RPa: 1.25; 95% CI: 1.15–1.35), being from the highlands region (RPa: 1.18; 95% CI: 1.09–1.28) or jungle (RPa: 1.30; 95% CI: 1.15–1.47), having a relative that is a healthcare professional (PRa: 1.16; 95% CI: 1.06–1.28), using a medical source of information (PRa: 1.28; 95% CI: 1.17–1.41), and trusting in the possible effectiveness of vaccines (PRa: 1.40; 95% CI: 1.29–1.51). The main reason for not participating in the trial was the possibility of developing side effects (69.80%). CONCLUSION: There is an urgent need to generate a perception of safety in COVID-19 vaccine clinical trials, to increase the population's intention to participate in these studies, and to provide evidence-based information about the vaccine. Since the beginning of the Coronavirus Disease 2019 (COVID-19) pandemic, more than 255 million confirmed cases, and about 5 million deaths have been reported worldwide, which has required the scientific community to develop preventive measures and possible treatments. [1] Among them, the accelerated development of vaccine candidates has represented one of the most promising measures for the early control of the pandemic. [2] In January 2020, the genetic sequence of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) was published, encouraging the world to develop a potential vaccine. [3] Since then, more than 194 vaccines have been developed in the preclinical phase and more than 132 candidates have reached the clinical evaluation phase. [4] In Peru, phase III clinical trials of vaccines were conducted to evaluate adverse effects and efficacy. [5] Due to the high demand for vaccines worldwide, the scarce resources of middle and low-income countries, and the uncertainty on the efficacy of vaccines against coronavirus variants, there is still a need to continue developing more vaccine candidates. [6, 7] Therefore, it became very relevant to promote the participation of the population in clinical trials. Although participating in clinical trials brings multiple public health benefits [8] and accelerates vaccine development, which could subsequently save millions of lives, [9] the ethical value of experimental studies has been questioned. [10] The rapid development of potential vaccines has led to mistrust and concern about their quality and safety in the population, [11, 12] creating barriers to participate in vaccine clinical trials. In this context, our study aims to evaluate the factors associated with the intention to participate in COVID-19 vaccine clinical trials in Peruvian population during the year 2020. We hope our findings could be used to implement strategies that allow greater participation, to improve recruitment and acceptance of vaccines under development, and to generate evidence to serve as a starting point for considerations in future pandemics. We conducted a Cross-sectional analytical study based on a database previously collected in the general Peruvian population in September 2020, which methodology was previously reported. [13] For the present study, we included individuals older than 18 years, with Peruvian nationality and residency. We excluded those with a history of COVID-19. We used a questionnaire that consisted of the following sections: 1) sociodemographic characteristics (sex, age, comorbidities), 2) preventive practices and perspectives on the COVID-19 for persons without a history of COVID-19 (including intention to vaccinate), 3) practices and perspectives on the COVID-19 in persons with a history of COVID-19, only sections 1 and 2 were used for this study. The validity of the questionnaire was reviewed by a group of clinicians and/or researchers. The Cronbach's Alpha showed good survey reliability (0.70). Intention to participate in COVID-19 clinical trials was defined as an individual's desire to participate in an experimental study, in which he or she may receive a vaccine candidate or placebo, considering that the intervention may or may not provide health benefits for the participant. Our study evaluated this outcome with the question "Would you volunteer for a new vaccine to be tested on you?", having two answer choices: "no" and "yes". Other evaluated variables were: sex (female, male), age (young, adult or older adult), marital status (single, married or cohabiting), educational level (higher education, secondary education or a lower level), region (coast, highlands, jungle), area of residence (urban and rural), employment status (no, yes), social class (low, mediumhigh), healthcare professional within the family (no, student of health sciences, healthcare professional), source where the information about COVID-19 was obtained (social networks, press media, medical information, friends and family), comorbidities for COVID-19 (no, yes), family member diagnosed with COVID-19 (no, yes), family member died of COVID-19 (no, yes), perspectives about the disease (none or little and a lot), opinion about vaccine candidates (I am not informed, not effective, effective), and reasons for not participating in a clinical trial (because it may cause other diseases, because it would be of foreign origin, because I do not believe in the efficacy of vaccines, because it could have microchips to track people, other). Data processing and statistical analysis were performed in Stata v16.0 (StataCorp, TX, USA). Absolute and relative frequencies of categorical variables were estimated, and the chi-square test was used to compare the proportions between groups. To assess the factors associated with the intention to participate in vaccine clinical trials, Poisson regression models were used to calculate the crude (RPc), and the adjusted (RPa) prevalence ratios with their respective 95% confidence intervals. For the adjusted analysis, an epidemiological model was followed, including all the variables evaluated in the crude analysis. The primary study was evaluated and approved by the Institutional Ethics Committee of the Universidad Peruana Unión (Code: 2020-CEUPeU-00020). The initial survey was anonymous, and had extended consent for the use of respondents' data for future research. The primary study evaluated a total of 3,630 individuals, of whom 399 were excluded because they did not respond to the outcome of interest, leaving 3,231 participants included in the present study. A total of 62.7% were female, 84.5% were young, 87.6% were single, 76% had a higher education level, 48.9% belonged to the coast region, 84.8% were from the urban areas, and 85.3% had no comorbidity for COVID-19 ( Table 1) . The prevalence of intention to participate in COVID-19 vaccine clinical trials was 44.1%. Regarding the reasons for not participating in a clinical trial, 69.8% of participants thought that the biologic could cause side effects, while 8.6% was doubtful of its efficacy, 2.6% considered that the vaccine could contain tracking microchips, 2.1% stated that the main reason was the foreign origin of the biologic, and finally 16.6% gave other reasons. Factors associated with the intention to participate in COVID- 19 Table 2) . Around the world, clinical trials are the cornerstone for the development of COVID-19 vaccines. In Latin America, implementation of multisite clinical trials had face challenges, such as to limited facilities, fake news about vaccines and insufficient number of participants. [14] Additionally, political scandals could have affected the credibility of COVID-19 vaccines clinical trials [15] and generated less participation of the population in these studies. [16] Our study revealed that 44% of respondents intended to participate in COVID-19 vaccine clinical trials. Detoc M et al. reported 47% in France [17] and Abu-Farha RK et al. found 36% of intention in Jordan, not very different from the present study. [18] The variation among different reports could be explained by cultural and religious factors, [19] and by the COVID-19 pandemic impact on these countries. Under these circumstances, countries with higher morbidity and mortality from COVID-19 [1] such as Peru and France, could have a population with higher intention to participate in clinical trials, given the urgency for a faster development of COVID-19 vaccines. [17] Interestingly, these studies [17, 18] included recovered COVID-19 cases; therefore, the intention to participate in clinical trials may be overestimated. [20] Before the COVID-19 pandemic, only a minority of clinical trials had been conducted in Peru. [21] For this reason, the knowledge and confidence level to participate in clinical trials among Peruvian population could be lower than those reported in other region countries of South America. On another hand, in the context of COVID 19 pandemic, the participation in vaccines clinical trials may be considered a potential therapeutic intervention and an opportunity to collaborate with the community. [22] It is worth mentioning that the Peruvian government has had a crucial role in the pandemic to fight misinformation and to increase the acceptance of clinical trials by providing correct information, [23] emphasizing the contribution of clinical trials in people's health and highlighting that trials are regulated by local and international ethics committees. [21] In 2020, approximately 29 COVID-19 clinical trials were conducted in Peru, 5 of them about COVID-19 vaccines. [24] Frequently, younger population are enrolled in these trials, which was also noted in previous studies and the current one. [25] The higher intention to participate of this age group is probably due to altruism and the adequate information received by public health personnel. [25] Another potential explanation for this finding may be that the majority of young people were on an education system, [26] therefore they may have an acceptable knowledge about COVID-19 vaccines. In addition, comorbidities are lower in this age group; thus, risk of potential side effects could be perceived as low by the participants. However, the massive enrollment of young population in COVID-19 vaccine clinical trials could provoke potential bias of representative sample sizes, making very difficult to extrapolate the results to the elderly and population with comorbidities. [27] Interestingly, more than half of the respondents did not intend to participate due the possible development of side effects from the vaccine candidate. Some studies attribute this finding to the poor access of information about study processes, and lack of knowledge of ethical and legal aspects of COVID-19 vaccine clinical trials. [28] In order to improve this aspect, we believe that the Peruvian Ministry of Health should take the lead in educating the population about COVID 19 clinical trials through social media, newscasts, social networks, personalized messages to telephone numbers and others. [29] Another interesting finding of the present study was the small proportion of population that believed COVID-19 vaccines contained tracking microchips. This conspiracy theory originated from internet forums where it was mentioned that the Microsoft founder contributed with vaccine development to spread microchips around the world and control human population. [30] This theory spread through internet, especially by social networks that do not have regulations against fake news. [31] There are some strategies that have been implemented worldwide to control this problem, such as public health campaigns for social networks users, autoregulation of social network companies, [31] spreading official information by government channels [23] and imprisonment for fake news promoters. [32] However, such efforts have not been sufficient. [33] In previous studies, low education level, coming from rural areas, and low socioeconomic level were associated with a decreased intention to participate in COVID-19 vaccine clinical trial. [34, 35] In Peru, these findings were found in the highlands and jungle. [36] However, in our study, coming from the highlands or jungle were associated with a higher intention to participate in COVID-19 vaccine clinical trials, which is surprising given the disproportionate higher incidence of COVID-19 infection in the coast of Peru that could make us think that this population would be more interested in participating in clinical trials. A possible explanation could be that the population from coast of Peru has more access to conspiracy theories by the media, leading to a lower intention to participate. [36, 37] Also, we found the male gender was independently associated to intention to participate in COVID-19 vaccine clinical trial. Similar results were reported in France [17] ; however, in China the intention in female population was significantly higher. [22] We believe that specific communication strategies are needed in Peru to decrease the gender difference. This finding may be secondary to the traditional education in Peru, where men feel responsible for protecting the members of their family. [38] Given the low intention to participate in clinical trials found in this study, we believe that the Peruvian government should increase its efforts to provide adequate information about the efficacy and safety of COVID-19 vaccines, and on this way, improving the culture of vaccination and participation in clinical trials. There is also a need to implement strategies to counteract the spread of misinformation in Peru. Artificial intelligence has demonstrated an accuracy of 98% to detect fake news, and should be considered in places with poor participation in clinical trials. [39] The study had some limitations. First, our sample is not completely representative of the Peruvian general population. Second, the use of social networks to recruit surveys depends on the accessibility of participants' internet services, and their willingness to participate in online surveys. Third, the phase of the clinical trial was not specified, and the intention to participate may vary between the different phases of the clinical trials. Despite these limitations, this is the first study in the Peruvian population to evaluate the factors associated with the intention to participate in the COVID-19 vaccine trial. This study involved a large sample size of 3,231 Peruvian participants from different regions of the country. In conclusion, less than half of the participants had the intention to participate in COVID-19 vaccine clinical trials. The main reasons for not participating were the possible side effects of the vaccine candidates, distrust in its efficacy, and the belief that the vaccine candidate would contain microchips. Likewise, almost half of the participants were not informed about the preventive nature of a vaccine. Among the factors associated with a higher intention to participate, we found that being informed from medical sources, having a healthcare professional in the family, being from the highlands or jungle region and being male increased the intention among individuals. These findings should alert the Peruvian government of the need to implement public policies to increase the awareness on vaccine clinical trials. We recommend targeting population with characteristics associated with high acceptance in vaccine trials to ensure an adequate enrollment in clinical studies. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. All authors attest they meet the ICMJE criteria for authorship Tables Table 1. Bivariate analysis World Health Organization. WHO Coronavirus Disease (COVID-19) Dashboard Vaccines for COVID-19: The current state of play The COVID-19 vaccine development landscape World Health Organization. COVID-19 vaccine tracker and landscape Vaccine COVID-19 Peru. Phase III Trial Study The Organization for Economic Co-operation and Development. Access to COVID-19 vaccines: Global approaches in a global crisis World Health Organization. Viral variants and their effects on COVID-19 vaccines Human Challenge Studies to Accelerate Coronavirus Vaccine Licensure So much at stake: Ethical tradeoffs in accelerating SARSCoV-2 vaccine development Human Infection Challenge Studies: a Test for the Social Value Criterion of Research Ethics The rush to create a covid-19 vaccine may do more harm than good Future pandemics and vaccination: Public opinion and attitudes across three European countries Prácticas de prevención y control frente a la infección por Sars-Cov2 en la población peruana. Revista Del Cuerpo Médico Hospital Nacional Almanzor Aguinaga Asenjo The landscape of COVID-19 clinical trials in Latin America and the Caribbean: assessment and challenges* Scandal over COVID vaccine trial at Peruvian universities prompts outrage Peruvian COVID-19 vaccine scandal spreads Intention to participate in a COVID-19 vaccine clinical trial and to get vaccinated against COVID-19 in France during the pandemic Public Willingness to Participate in COVID-19 Determinants of COVID-19 vaccine acceptance in the US The willingness of the Saudi Arabian population to participate in the COVID-19 vaccine trial: A case-control study How to increase the number of clinical trials in Peru? Interest in COVID-19 vaccine trials participation among young adults in China: Willingness, reasons for hesitancy, and demographic and psychosocial determinants Regulation of clinical trials for COVID-19 in Peru Barriers and motivations for participation in preventive vaccine clinical trials: Experience of 5 clinical research sites 27% of the Peruvian population are young people Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates Do clinical trials contribute to the development of research in Peru: how can this be achieved? Five rules for evidence communication The epic battle against coronavirus misinformation and conspiracy theories Social media and vaccine hesitancy: new updates for the era of COVID-19 and globalized infectious diseases Twitter EU action in Spain in the face of the disinformation "infodemic" by COVID-19 Attitudes Toward a Potential SARS-CoV-2 Vaccine Predictors of intention to vaccinate against COVID-19: Results of a nationwide survey Cultural identity in Peru: background, differences between regions and influence of modernism World Health Organization. Episode #24 -Vaccine myths vs science Identity, family responsibility and the exercise of paternity in men in the State of Mexico FNDNet -A deep convolutional neural network for fake news detection ☐The authors declare the following financial interests/personal relationships which may be considered as potential competing interests